How much revenue does 0913693 B.c. make?

0913693 B.c. reported 353,735 CAD in revenue for fiscal year 2022, about flat from 353,735 CAD in fiscal year 2021. In Q3 2023 revenue was 88,434 CAD.

What companies are similar to 0913693 B.c.?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Gsrx Industries Inc. (GSRX), Bioasis Technologies Inc. (BIOAF), Winston Pharmaceuticals, Inc. (WPHM), Gelesis Holdings, Inc. (GLSHQ).

0913693 B.c. Ltd. (REPCF) Stock

Q: What does 0913693 B.c. do?

C. , a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons.

About 0913693 B.c. Ltd.

0913693 B.C. Ltd., a regenerative medicine company, develops autologous cell therapies for the treatment of functional cellular deficits. Its treatments use autologous cell therapy to treat chronic tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include R...

At a glance

0913693 B.c. reported revenue of 353,735 CAD for fiscal year 2022, about flat from fiscal year 2021, and net income of -743,228 CAD. In Q3 2023 (the quarter ended September 30, 2023) revenue was 88,434 CAD, about flat from a year before.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.